Gamida Cell Ltd. (NASDAQ:GMDA - Get Rating) - Analysts at Oppenheimer lifted their FY2025 EPS estimates for Gamida Cell in a note issued to investors on Tuesday, May 10th. Oppenheimer analyst M. Breidenbach now anticipates that the company will earn $0.32 per share for the year, up from their prior estimate of $0.31.
GMDA has been the subject of a number of other research reports. JMP Securities reiterated a "buy" rating and issued a $17.00 price target on shares of Gamida Cell in a research note on Tuesday, February 1st. Piper Sandler reduced their price target on shares of Gamida Cell from $13.00 to $6.00 in a research report on Tuesday. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Gamida Cell in a research note on Wednesday, March 16th. Finally, Zacks Investment Research cut shares of Gamida Cell from a "buy" rating to a "hold" rating in a research note on Monday, April 4th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $12.39.
Shares of GMDA stock traded up $0.16 during trading on Friday, reaching $2.36. The company's stock had a trading volume of 5,601 shares, compared to its average volume of 1,609,648. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 1.63. The stock's 50-day moving average price is $3.46 and its 200 day moving average price is $3.20. Gamida Cell has a 1-year low of $2.10 and a 1-year high of $6.94. Gamida Cell (NASDAQ:GMDA - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.34). During the same quarter last year, the firm earned ($0.34) EPS.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Morgan Stanley increased its holdings in shares of Gamida Cell by 152.1% during the second quarter. Morgan Stanley now owns 72,586 shares of the company's stock valued at $465,000 after purchasing an additional 43,794 shares during the period. BlackRock Inc. boosted its position in Gamida Cell by 4.6% during the 3rd quarter. BlackRock Inc. now owns 361,759 shares of the company's stock worth $1,418,000 after acquiring an additional 15,761 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Gamida Cell by 226.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 79,025 shares of the company's stock valued at $310,000 after buying an additional 54,820 shares during the last quarter. Stonepine Capital Management LLC lifted its holdings in shares of Gamida Cell by 288.8% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,724,201 shares of the company's stock valued at $6,759,000 after buying an additional 1,280,694 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Gamida Cell by 153.3% in the 3rd quarter. Renaissance Technologies LLC now owns 531,184 shares of the company's stock worth $2,082,000 after purchasing an additional 321,484 shares during the last quarter. Hedge funds and other institutional investors own 47.12% of the company's stock.
About Gamida Cell (Get Rating)
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Gamida Cell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gamida Cell wasn't on the list.
While Gamida Cell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
